Hepatocellular Carcinoma

Group Leader:

Prof Teh Bin Tean

Senior Principal Investigator,
CSI Singapore

Hepatocellular carcinoma (HCC) is a challenging medical problem worldwide especially in China and Asia, and the only FDA-approved drug (sorafenib) for advanced stage HCC management is an expensive and a marginal therapy. Despite extensive knowledge on liver cancer etiology and various cell signaling pathways in cancer cells, there is still no effective therapy for this aggressive malignancy. Formed in the late 2010, the CSI Hepatocellular Carcinoma Group plans to encompass major aspects of cancer biology, genetics, translational medicine and clinical cares, including prevention, early diagnosis and effective treatment. The HCC group has about 12 active members, conduct bi-monthly joint NCCS-NUS or NUH-SGH scientific meetings at alternate venues, and organise annual retreat or scientific conferences with invited overseas experts in HCC. In Aug 2010, the team has begun collaborating with industry partners, to sequence at deep genome-wide scale 100 pairs of HCC tumours in order to dissect and decode the underlying genetic mutations that drive HCC oncogenesis, metastasis and drug resistance. The new information obtained will lead to treatment of HCC patients in more personalized and effective methods.